CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Regulation FD disclosure
- 4 Open-market buy General Counsel bought 2,000 shares at $2.48 ($4,960)
- 4 Open-market buy Chief Financial Officer bought 4,000 shares at $2.49 ($9,960)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- 4 Open-market buy Chief Executive Officer bought 4,500 shares at $3.50 ($15,750)
- 4 Open-market buy Chief Financial Officer bought 3,000 shares at $3.40 ($10,200)
- S-3 Offering Registration Statement
- 10-Q Report Quarterly Report
- 4 Open-market buy Chief Financial Officer bought 3,000 shares at $3.92 ($11,760)
- 10-Q Report Quarterly Report
- 8-K Event Executive or director change
- 4 Open-market buy Chief Medical Officer bought 2,000 shares at $5.26 ($10,520)
- 4 Open-market buy Chief Executive Officer bought 3,000 shares at $5.11 ($15,330)
- 4 Open-market buy Chief Financial Officer bought 2,000 shares at $4.74 ($9,480)
Page 14 of 18 · 353 filings